Noronha, Avertano B., MD

Associate Professor

Address: 5841 S. Maryland Ave., MC 2030
Chicago, IL 60637-1470
Telephone: 773-702-6532
Secretary: Gretchen Hendrie
Patient Calls: 773-702-6222
Fax: 773-702-9076
Dr. Noronha discusses multiple sclerosis on Chicago WGN News at Noon (April 21, 2006)



Education & Training
  • M.D., Christian Medical College, India
  • Internship, Christian Medical College, Brown Memorial Hospital
  • Residency, Northwestern Memorial Hospital, Chicago
  • Clinical and Research Fellow in Neuroimmunology, University of Chicago
  • Board Certified in Neurology
Clinical Interests
  • Dr. Noronha’s work is in the area of neuroimmunology, clinical neurology, and neurological education. Dr. Noronha has a strong interest and considerable experience in general clinical neurology as well as in the fields of multiple sclerosis, lupus and the vasculitides, autoimmune diseases, inherited neurologic diseases, and the neurological complications of medical disorders and pregnancy. This is reflected in the diversity of his outpatient clinics and his work in clinical trials.
Teaching
  • Course Director for BioSci 14107, “Workings of the Human Brain.”
Selected Publications
  1. Miller D, et al. The efficacy of natalizumab on magnetic resonance imaging (MRI) measures in patients with relapsing multiple sclerosis (MS): Results from the AFFIRM trial. Neurology 2005;64 (Suppl 1) A147, S16.005.
  2. Noronha A. The importance of early treatment of MS. International Journal of MS Care. 2005;7 (suppl 2).
  3. O’Connor P, et al. Safety, tolerability and immunogenicity of natalizumab: Results from the AFFIRM trial. Neurology 2005;64 (Suppl 1) A146, S16.004.
  4. Polman C, et al. Clinical Results from AFFIRM: A randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis (MS). Neurology 2005;64 (Suppl 1) A146, S16.003.
  5. Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, Yang M, Hulme A, O’Connor P, Miller DH. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol. 2004 Apr;251(4):407-13.
  6. Kappos L, et al. The incidence and clinical significance of antibodies to natalizumab: 2-year results from the AFFIRM study. J Neurol. 2004;252 (Suppl 2 ) 85, P492.
  7. O’Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA; Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004 Jun 8;62(11):2038-43.
  8. The BEYOND (Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose) programme: Efficacy yielding outcomes of a new dose. Neurology 2004;62(7, Suppl 5):A226, P06.086.
  9. The BEYOND (Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose) programme: Investigating further benefits with high-dose, high-frequency interferon-alpha treatment. Multiple Sclerosis 2004;10 (Suppl 2): S247-248, P601.
  10. Wolinsky JS, Pardo L, Stark Y, Silman S, Kadosh S, Zak B, Ladkani D, and the PROMiSe Study Group. Effect of glatiramer acetate on primary progressive multiple sclerosis: Initial analysis of the completed PROMiSe trial. Neurology 2004;62(7)(Suppl 5):A97, S12.001.
Back to Top